Targeted polyethylenimine/(p53 plasmid) nanocomplexes for potential antitumor applications
Source abstract
Abstract
Abstract The development of the tumor-targeting ability of nanocarriers is of paramount importance for gene delivery into tumor lesions as well as to avoid biotoxicity. Here we report the synthesis of the polyethyleneimine-fluorescein isothiocyanate-folic acid (PEI-FITC-FA) polymer, which could condense the tumor suppressor pp53 to form nanocomplexes. These targeted nanocomplexes exhibited favorable physical properties including a small size of <100 nm, exploiting the enhanced permeability and retention effect and tumor-targeting ability by binding to the overexpressed FA receptors on tumor cell surfaces. In addition, once the nanocomplexes are accumulating in the tumor tissue, the target functional ligand, FA, can selectively recognize the over-expressed FA receptor and subsequently remain on the tumor cell surface, which can significantly promote the tumor cell uptake because of the time- and concentration-dependent internalization caused by the enhanced interaction between nanocomplex and tumor cell. Our results indicated that PEI-FITC-FA/pp53 nanocomplexes could be efficiently delivered into tumor cells, and subsequently induce tumor cell apoptosis. Thus, the targeted cationic polymer PEI-FITC-FA could be used as an advanced nanocarrier for gene delivery.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration10.1016/j.ijpharm.2009.10.020 ↗
2. Human gene therapy: a brief overview of the genetic revolution
3. Challenges in DNA delivery and recent advances in multifunctional polymeric DNA delivery system10.1021/acs.biomac.7b00803 ↗
4. Design and development of polymers for gene delivery10.1038/nrd1775 ↗
5. Virus-inspired nucleic acid delivery system: linking virus and viral mimicry10.1016/j.addr.2016.07.005 ↗
6. Non-viral vectors for gene-based therapy10.1038/nrg3763 ↗
7. Well-defined reducible cationic nanogels based on functionalized low-molecular-weight PGMA for effective pDNA and siRNA delivery10.1016/j.actbio.2016.06.006 ↗
8. Tumor-targeted aggregation of pH-sensitive nanocarriers for enhanced retention and rapid intracellular drug release10.1039/C4PY00575A ↗
9. Tumor-acidity activated surface charge-conversion of polymeric nanocarriers for enhanced cell adhesion and targeted drug release10.1002/marc.201400362 ↗
10. Multifunctional core/shell nanoparticles cross-linked polyetherimide-folic acid as efficient Notch-1 siRNA carrier for targeted killing of breast cancer10.1038/srep07072 ↗
11. N-Isopropylacrylamide-modified polyethylenimine-mediated p53 gene delivery to prevent the proliferation of cancer cells10.1016/j.colsurfb.2015.03.032 ↗
12. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer10.1016/j.biomaterials.2008.04.036 ↗
13. Tumor-targeted RNA-interference: functional non-viral nanovectors10.1016/B978-0-12-385524-4.00004-0 ↗
14. Star polymers: advances in biomedical applications10.1016/j.progpolymsci.2015.02.002 ↗
15. Macrocycle-wrapped polyethylenimine for gene delivery with reduced cytotoxicity10.1039/C8BM00022K ↗
16. Chitosan: an update on potential biomedical and pharmaceutical applications10.3390/md13085156 ↗
17. Design and characterization of a magnetite/PEI multifunctional nanohybrid as non-viral vector and cell isolation system10.1016/j.ijpharm.2016.12.042 ↗
18. Polyethylenimine: a versatile, multifunctional non-viral vector for nucleic acid delivery10.1016/j.msec.2016.07.066 ↗
19. Polyethyleneimine-based nanocarriers for gene delivery10.2174/1381612821666151027152907 ↗
20. Multifunctional PEI-entrapped gold nanoparticles enable efficient delivery of therapeutic siRNA into glioblastoma cells10.1039/C6BM00708B ↗
21. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression10.1038/cdd.2017.169 ↗
22. Olivier · 2002
23. Shaping genetic alterations in human cancer: the p53 mutation paradigm10.1016/j.ccr.2007.10.001 ↗
24. Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour10.1038/ncomms7456 ↗
25. Ultrasensitive electrochemical immunosensing of tumor suppressor protein p53 in unprocessed human plasma and cell lysates using a novel nanocomposite based on poly-cysteine/graphene quantum dots/gold nanoparticle10.1016/j.ijbiomac.2017.11.006 ↗
26. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy10.2174/1381612811319180009 ↗
27. Mutant p53 in cancer: accumulation, gain-of-function and therapy10.1016/j.jmb.2017.03.030 ↗
28. Co-delivery of proapoptotic peptide and p53 DNA by reduction-sensitive polypeptides for cancer therapy10.1039/C5BM00046G ↗
29. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology10.1158/0008-5472.CAN-12-4561 ↗
30. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect10.2147/IJN.S47129 ↗
31. Targeted drug delivery via the folate receptor10.1016/S0169-409X(99)00062-9 ↗
32. Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo10.1016/j.nano.2016.06.014 ↗
33. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice10.1016/j.jconrel.2004.01.002 ↗
34. Targeting ligand-functionalized photothermal scaffolds for cancer cell capture and in situ ablation10.1039/C7BM00639J ↗
35. Targeting CCL21-folic acid-upconversion nanoparticles conjugates to folate receptor-α expressing tumor cells in an endothelial-tumor cell bilayer model10.1016/j.biomaterials.2013.03.029 ↗
36. A holistic approach to targeting disease with polymeric nanoparticles10.1038/nrd4503 ↗
37. Revisiting the value of competition assays in folate receptor-mediated drug delivery10.1016/j.biomaterials.2017.05.034 ↗
38. Development of a novel folate-modified nanobubbles with improved targeting ability to tumor cells10.1016/j.ultsonch.2017.01.013 ↗
39. Folate-targeted non-viral DNA vectors for cancer gene therapy10.1016/S0958-1669(00)00082-3 ↗
40. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC1710.18632/oncotarget.8282 ↗
41. Folate receptor alpha as a tumor target in epithelial ovarian cancer10.1016/j.ygyno.2007.11.020 ↗
42. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue10.0000/PMID19189636 ↗
43. Folate receptor-targeted and cathepsin B-activatable nanoprobe for in situ therapeutic monitoring of photosensitive cell death10.1021/acs.analchem.5b00429 ↗
44. Dual-targeting multifuntional mesoporous silica nanocarrier for codelivery of siRNA and ursolic acid to folate receptor overexpressing cancer cells10.1021/acs.jafc.7b03047 ↗
45. Synthesis of poly(alpha,beta-[N-(2-hydroxyethyl)-L-aspartamide])-folate for drug delivery10.1163/156856209X441991 ↗
46. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin
47. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
48. Rational design of cancer nanomedicine: nanoproperty integration and synchronization10.1002/adma.201606628 ↗
49. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking10.1002/smll.201201390 ↗
50. Dual tumor-targeted poly(lactic-co-glycolic acid)–polyethylene glycol–folic acid nanoparticles: a novel biodegradable nanocarrier for secure and efficient antitumor drug delivery10.2147/IJN.S136488 ↗
51. The role of micelle size in tumor accumulation, penetration, and treatment10.1021/acsnano.5b02017 ↗
52. Synthesis and characterization of pyrene modified polyethylenimine as a novel fluorescent self-reporter for gene condensation10.1016/j.matchemphys.2018.02.027 ↗
53. The role of surface functionality in determining nanoparticle cytotoxicity10.1021/ar3000647 ↗
54. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening10.1021/ar300022h ↗
55. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis10.1016/j.molcel.2007.05.017 ↗
56. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy10.1002/hed.20529 ↗
57. From tumor prevention to therapy: empowering p53 to fight back10.1016/j.drup.2012.10.001 ↗
58. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity10.1101/gad.298463.117 ↗